- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06425705
Impact of Silymarin Adjunct Therapy on Proteinuria in Type 2 Diabetic Patients on RAS Inhibitors
Evaluating the Outcome of Silymarin as an Adjunct Therapy to Renin-Angiotensin System Inhibitors in Proteinuric Type 2 Diabetic Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
After securing the approval from the Ethical Review Board of hospital, this study was conducted in the Nephrology Department, Lahore General Hospital, Lahore. All patients diagnosed with Type 2 Diabetes Mellitus was assessed based on the previously defined inclusion and exclusion criteria. Informed consent was obtained from all eligible participants who agreed to participate in the study.
Baseline Data Collection: Upon enrollment, demographic and clinical information including age, gender, duration of diabetes, baseline renal function tests, current medication use, and baseline measures of HBA1c, FBS, RBS and proteinuria were collected. This information was provided a comprehensive profile of each participant at the start of the study.
Treatment Allocation: Patients was randomly assigned into two groups using a lottery method:
- Group A: received 140 mg of silymarin administered orally three times daily, alongside their standard treatment with renin-angiotensin system inhibitors.
- Group B: received placebo capsule three times a day alongside their standard treatment with renin-angiotensin system inhibitors.
Monitoring and Follow-up Assessments: Participants was assessed for outcomes after at one month and 3 months to monitor changes in proteinuria and renal function. Specific tests were included:
- Measurement of Urinary Albumin-Creatinine Ratio (UACR): Participants were required to provide 24-hour urine specimens at one month and three months into the study. To ensure that the urine samples are not affected by external factors, patients was instructed to maintain their usual physical activities and avoid strenuous exercises the evening before the assessment days. Proteinuria was quantified using immunoturbidimetry.
- Assessment of Serum Creatinine and Calculation of eGFR to Monitor Renal Function: The estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI formula at one month and three months. These assessments were help to monitor any changes in renal function over the course of the study.
- Measurement of HbA1c levels after 3 months. The data was recorded meticulously using standardized data collection forms. Data was analyzed using SPSS version 26.0. Baseline characteristics of participants (age, gender, duration of diabetes, baseline renal function tests, HbA1c, FBS, RBS) were summarized using means and standard deviations for continuous variables, and frequencies and percentages for categorical variables. Changes in UACR, eGFR, and HbA1c from baseline to one month and three months were compared between Group A (silymarin) and Group B (placebo) using independent t-tests or Mann-Whitney U tests, depending on the normality of the data. Analysis of Covariance (ANCOVA) was used to adjust for any baseline imbalances and potential confounders between the two groups. Repeated measures ANOVA were employed to analyze changes over time within and between treatment groups for UACR, eGFR, and HbA1c levels, accounting for within-subject correlation over the assessment periods. All statistical tests were two-sided, and a p-value of less than 0.05 was considered statistically significant.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Punjab
-
Lahore, Punjab, Pakistan, 54000
- Lahore General Hospital, Lahore
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged 35-70 years.
- Both male and female with Type II diabetes.
- Overt proteinuria defined by urinary albumin excretion > 300 mg/24 hr. in 2 consecutive determinations despite treatment with highest FDA recommended doses of an angiotensin converting enzyme inhibitor or angiotensin receptor blocker for at least 6 months.
- Treatment of hyperglycemia with (but not limited to) an oral hypoglycemic agent or insulin (If a SGLT2 inhibitors is used, stable dose for at least 3 months).
- Treatment of hypercholesterolemia with (but not limited to) one medication from the class statins.
- Patients using stable dose of Non-Dihydropyridine Calcium Channel Blockers for at least 6 months as antihypertensive.
- Presence of diabetic retinopathy.
- Signing informed consent.
Exclusion Criteria:
- Type I diabetes.
- Advanced chronic kidney disease defined by estimated GFR < 30 ml/min/1.73 m2
- Severely uncontrolled diabetes defined by HbA1C > 10%.
- Uncontrolled hypertension defined by SBP >140 mmHg or DBP >90 mmHg despite antihypertensive therapy.
- Patients with organ transplant history.
- Secondary forms of hypertension with defined etiology other than diabetes mellitus.
- Other renal diseases.
- Chronic Heart Failure with NYHA class III or IV.
- Active infection.
- Pregnancy.
Use of one of the following medications within 2 months prior to enrollment in the study:
- Non-steroidal anti-inflammatory agents.
- Antioxidants supplements including vitamin E, vitamin C, N-acetyl- cysteine (NAC), Pentoxifylline, Lipoic acid, Fish-oil extracts (omega-3 fatty acids), Soy extracts (isoflavones), Green-tea preparations, Pomegranate extracts, Grape extracts.
- Active malignancy.
- History of drug or alcohol dependency.
- Psychiatric or neurological condition, preventing aware consent to the study and/or adherence to the study protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group Silymarin
Received 140 mg of silymarin administered orally three times daily, alongside their standard treatment with renin-angiotensin system inhibitors.
|
140 mg of silymarin administered orally three times daily, alongside their standard treatment with renin-angiotensin system inhibitors.
Other Names:
|
Placebo Comparator: Group Placebo
Received placebo capsule three times a day alongside their standard treatment with renin-angiotensin system inhibitors.
|
placebo capsule three times a day alongside their standard treatment with renin-angiotensin system inhibitors.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the urinary albumin-creatinine ratio (UACR) from baseline
Time Frame: Outcomes monitored at one and three-month intervals
|
It was measured quantitatively by comparing the urinary albumin-creatinine ratio (UACR) in mg/g between initial recruitment and subsequent follow-up visits at one and three months.
|
Outcomes monitored at one and three-month intervals
|
Change in estimated glomerular filtration rate (eGFR) from baseline
Time Frame: Outcomes monitored at one and three-month intervals
|
eGFR was calculated using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula, which incorporates serum creatinine, age, sex, and race.
The outcome measure was the change in eGFR in mL/min/1.73
m² at one month and three months compared to the baseline value.
|
Outcomes monitored at one and three-month intervals
|
Change in HbA1c levels from baseline
Time Frame: Outcomes monitored after three-month.
|
It was measured quantitatively by comparing the HbA1c levels in percentage (%) between initial recruitment and subsequent follow-up visit after three months.
|
Outcomes monitored after three-month.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Muhammad Irfan Jamil, MBBS, FCPS, Lahore General Hospital, Lahore
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Urologic Diseases
- Urological Manifestations
- Endocrine System Diseases
- Urination Disorders
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Proteinuria
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Antioxidants
- Silymarin
Other Study ID Numbers
- LahoreGeneralH1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
-
DiabeloopUniversity Hospital, Grenoble; AGIR à Dom; Icadom; Centre Hospitalier Annecy Genevois and other collaboratorsCompletedDiabetes Mellitus Type 2 - Insulin-TreatedFrance
Clinical Trials on Silymarin
-
Vanderbilt UniversityWithdrawn
-
Isfahan University of Medical SciencesMadaus IncUnknownIron Overload | Beta-thalassemia MajorIran, Islamic Republic of
-
University of Sao Paulo General HospitalUniversity of Sao PauloCompletedHealthy | Inflammatory Bowel Diseases | Insulin Resistance | Overweight and ObesityBrazil
-
Madaus IncUniversity of Pennsylvania; Beth Israel Deaconess Medical Center; University... and other collaboratorsCompletedNon-alcoholic SteatohepatitisUnited States
-
Shiraz University of Medical SciencesCompletedImmune AbnormalitiesIran, Islamic Republic of
-
Herbert Irving Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedLeukemia | Drug/Agent Toxicity by Tissue/OrganUnited States, Canada
-
Ramathibodi HospitalCompleted
-
National Center for Complementary and Integrative...Office of Dietary Supplements (ODS)CompletedHepatitis C, Chronic
-
Tanta UniversityNot yet recruiting